濮阳市东方医院专不专业(濮阳东方医院男科治疗阳痿技术好) (今日更新中)

The World Series starts Tuesday, which means a player with either the Tampa Bay Rays or the Los Angeles Dodgers could help Americans score free tacos from Taco Bell.For the ninth year in a row, Taco Bell announced they are bringing back its "Steal a Base, Steal a Taco" incentive, which means rewards members can score free tacos if a player steals a base in the World Series.And this year, fans will have the opportunity to claim a free Doritos Locos taco hours after the first base is stolen through a code on the Taco Bell app.“Through a season and a year like no other, we are proud to bring back a promotion that fans can always count on and are thrilled to partner with the league again to provide free tacos for all of America – no matter what team you root for,” said Nikki Lawson, Taco Bell’s Chief Global Brand Officer said in a news release.The taco usually sells for .89, and new members must create an account on the app by 8 p.m. ET on Oct. 20. 968

The Trump administration has decided to refer every person caught crossing the border illegally for federal prosecution, a policy that could result in the separation of far more parents from their children at the border.The move would also mean that even if immigrants caught at the border illegally have valid asylum claims, they could still end up with federal criminal convictions on their record regardless of whether a judge finds they have a right to live and stay in the US.Homeland Security Secretary Kirstjen Nielsen officially enacted the policy on Friday, according to a Department of Homeland Security official speaking on condition of anonymity. It corresponds with a Department of Justice "zero-tolerance policy" for illegal border crossings, under which Attorney General Jeff Sessions has ordered federal prosecutors to pursue criminal charges against all referrals for illegally crossing the border, as possible. 936

The RV industry has seen a significant increase in rentals and sales over the summer. One company, RVshare, reported more than a 1,000% increase in rentals.Now, the trend seems to be moving beyond just a summer vacation alternative. Some are turning to it as a new way to home-school and work during this pandemic.Some families are turning these RVs into their primary or secondary homes."I think it is difficult for families to be cooped up," said Julie Partridge.Partridge was already considering making the switch to RV life before the pandemic, but after five months of social distancing and quarantining in her home, she decided to finally do it.She sold the family home and hit the road to live, home-school her kids and work from an RV."Obviously our camper is much smaller than our house,” said Partridge. “Substantially smaller, but you have this vast open world available to you. You feel less cooped up in this camper than you do in this 3,000 square foot house."She also feels the move to full-time RV life this fall will also give her kids a unique educational opportunity."We really want to see the national parks,” said Partridge. “I want my kids to do the park ranger program. I want to use that as their science and social studies curriculum from the road. So, we are really excited about those parts."The Partridge family is just one of many either committing to or newly considering RV life in the fall, according to a survey done by the RV rental company RVshare."We have, from our survey, seen that over 30% of people are considering homeschooling from the road and over 40% of people are considering working from the road and that is something that is new to the industry," RVshare Jon Gray."You have school not opening on time, you have a lot of employers turning to work from anywhere models for the extended future and those things have made it to where RVs are appealing deep into the fall," said Gray.The pandemic has changed so much in our lives. Many people are looking to get away from the uncertainty and continued concern with it. This seems to be one way for some to do that."It is saving us money, it is teaching them lessons, it has really been kind of refreshing," said Partridge. 2224

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The US House of Representatives will vote on whether to legalize marijuana across the country in September. This would be the first time a chamber of Congress has ever voted on removing marijuana from the Controlled Substances Act.Cannabis was included as what is called a Schedule I drug under the Controlled Substances Act in 1970. Schedule I drugs are defined as having a high potential for abuse and no medical benefit. Other Schedule I drugs include heroin, LSD, ecstasy and peyote.On Friday, representatives were informed the MORE Act will come up for a vote in the September work period of the House.The MORE Act - Marijuana Opportunity Reinvestment and Expungement Act - will expunge some cannabis records and create grant opportunities for people who have been negatively impacted by the criminalization of marijuana in addition to removing it from its Schedule I classification, according to Politico.Marijuana is already legal in 11 states, despite the federal designation as a Schedule I drug.Senate Majority Leader Mitch McConnell is opposed to the act, and some say the odds of it passing the senate are very slim.Even if the MORE Act passes both chambers of Congress, it would not make sales of marijuana legal. Regulation of marijuana would be left to states to decide how to handle it. 1310

来源：资阳报